Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke

Ying Xian, Eric E. Smith, Xin Zhao, Eric D. Peterson, Daiwai M. Olson, Adrian F. Hernandez, Deepak L. Bhatt, Jeffrey L. Saver, Lee H. Schwamm, Gregg C. Fonarow

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


BACKGROUND AND PURPOSE-: The benefits of intravenous tissue-type plasminogen activator in acute ischemic stroke are time dependent, and several strategies have been reported to be associated with more rapid door-to-needle (DTN) times. However, the extent to which hospitals are using these strategies and their association with DTN times have not been well studied. METHODS-: We surveyed 304 Get With The Guidelines-Stroke hospitals joining Target: Stroke regarding their baseline use of strategies to reduce DTN times in the January 2008 to December 2009 time frame before the initiation of Target: Stroke and determined the association between hospital strategies and DTN times. RESULTS-: Among 5460 patients receiving tissue-type plasminogen activator within 3 hours of symptom onset in surveyed hospitals, the median DTN time was 72 minutes (interquartile range, 55-94). Reported use of the different strategies varied considerably. Of 11 hospital strategies analyzed individually by multivariable analysis, 3 strategies were independently associated with shorter DTN times. These included rapid triage/stroke team notification (209/304 [69%] hospitals, 8.1-minute reduction in DTN time), single-call activation system (190/304 [63%] hospitals, 4.3 minutes), and tissue-type plasminogen activator stored in the emergency department (189/304 [62%] hospitals, 3.5 minutes). When analyzed incrementally, hospitals that used a greater number of strategies had shorter DTN times with 1.3 minutes (adjusted mean difference) saved for each strategy implemented (14 minutes if all strategies were used). CONCLUSIONS-: Although the majority of participating hospitals reported using some strategy to reduce delays in tissue-type plasminogen activator administration for acute ischemic stroke, the strategies applied vary considerably and those most strongly associated with shorter DTN times were applied relatively less frequently.

Original languageEnglish (US)
Pages (from-to)1387-1395
Number of pages9
Issue number5
StatePublished - May 2014


  • Quality improvement
  • Quality of health care
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing


Dive into the research topics of 'Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke'. Together they form a unique fingerprint.

Cite this